AQST Quote, Financials, Valuation and Earnings

Cormedix has a net margin of -84.99% compared to Aquestive Therapeutics's net margin of -24.24%. Aquestive Therapeutics's return on equity of -- beat Cormedix's return on equity of -72.96%.

Aquestive Therapeutics has a consensus price target of $10.83, signalling upside risk potential of 196.8%. On the other hand Cormedix has an analysts' consensus of -- which suggests that it could grow by 89.62%. Given that Aquestive Therapeutics has higher upside potential than Cormedix, analysts believe Aquestive Therapeutics is more attractive than Cormedix.

Aquestive Therapeutics has a beta of 2.625, which suggesting that the stock is 162.493% more volatile than S&P 500. In comparison Cormedix has a beta of 1.543, suggesting its more volatile than the S&P 500 by 54.28%.

Aquestive Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Aquestive Therapeutics quarterly revenues are $13.5M, which are larger than Cormedix quarterly revenues of $11.5M. Aquestive Therapeutics's net income of -$11.5M is lower than Cormedix's net income of -$2.8M. Notably, Aquestive Therapeutics's price-to-earnings ratio is -- while Cormedix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics is 5.00x versus -- for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -84.99% compared to Aquestive Therapeutics's net margin of 8.48%. Aquestive Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 66.4%.

Aquestive Therapeutics has a consensus price target of $10.83, signalling upside risk potential of 196.8%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Aquestive Therapeutics has higher upside potential than Eli Lilly and, analysts believe Aquestive Therapeutics is more attractive than Eli Lilly and.

Aquestive Therapeutics has a beta of 2.625, which suggesting that the stock is 162.493% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Aquestive Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Aquestive Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aquestive Therapeutics quarterly revenues are $13.5M, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Aquestive Therapeutics's net income of -$11.5M is lower than Eli Lilly and's net income of $970.3M. Notably, Aquestive Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics is 5.00x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Omeros has a net margin of -84.99% compared to Aquestive Therapeutics's net margin of --. Aquestive Therapeutics's return on equity of -- beat Omeros's return on equity of --.

Aquestive Therapeutics has a consensus price target of $10.83, signalling upside risk potential of 196.8%. On the other hand Omeros has an analysts' consensus of -- which suggests that it could grow by 26.21%. Given that Aquestive Therapeutics has higher upside potential than Omeros, analysts believe Aquestive Therapeutics is more attractive than Omeros.

Aquestive Therapeutics has a beta of 2.625, which suggesting that the stock is 162.493% more volatile than S&P 500. In comparison Omeros has a beta of 1.973, suggesting its more volatile than the S&P 500 by 97.297%.

Aquestive Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics pays -- of its earnings as a dividend. Omeros pays out -- of its earnings as a dividend.

Aquestive Therapeutics quarterly revenues are $13.5M, which are larger than Omeros quarterly revenues of --. Aquestive Therapeutics's net income of -$11.5M is higher than Omeros's net income of -$32.2M. Notably, Aquestive Therapeutics's price-to-earnings ratio is -- while Omeros's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics is 5.00x versus -- for Omeros. Usually stocks with elevated PS ratios are considered overvalued.

Rockwell Medical has a net margin of -84.99% compared to Aquestive Therapeutics's net margin of 5.88%. Aquestive Therapeutics's return on equity of -- beat Rockwell Medical's return on equity of -5.32%.

Aquestive Therapeutics has a consensus price target of $10.83, signalling upside risk potential of 196.8%. On the other hand Rockwell Medical has an analysts' consensus of -- which suggests that it could grow by 212.5%. Given that Rockwell Medical has higher upside potential than Aquestive Therapeutics, analysts believe Rockwell Medical is more attractive than Aquestive Therapeutics.

Aquestive Therapeutics has a beta of 2.625, which suggesting that the stock is 162.493% more volatile than S&P 500. In comparison Rockwell Medical has a beta of 1.379, suggesting its more volatile than the S&P 500 by 37.916%.

Aquestive Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rockwell Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics pays -- of its earnings as a dividend. Rockwell Medical pays out -- of its earnings as a dividend.

Aquestive Therapeutics quarterly revenues are $13.5M, which are smaller than Rockwell Medical quarterly revenues of $28.3M. Aquestive Therapeutics's net income of -$11.5M is lower than Rockwell Medical's net income of $1.7M. Notably, Aquestive Therapeutics's price-to-earnings ratio is -- while Rockwell Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics is 5.00x versus 0.64x for Rockwell Medical. Usually stocks with elevated PS ratios are considered overvalued.